Calciphylaxis Market Size:
The calciphylaxis market size is growing with a CAGR of 8.6% during the forecast period (2025-2032), and the market is projected to be valued at USD 4,662.91 Million by 2032 from USD 2,409.59 Million in 2024. Additionally, the market value for 2025 attributes to USD 2,609.41 Million.
Calciphylaxis Market Scope & Overview:
Calciphylaxis is a disease characterized by calcium deposits and thrombotic occlusion of blood vessels. It is of two types, uremic and non-uremic. Further, the uremic type is caused by end-stage renal disease while non-uremic type is caused by obesity, diabetes, and autoimmune diseases. The symptom of this disease includes skin lesions, wound formation and calcification in major blood vessels. The diagnostic methods for this disease include skin biopsy, blood test, imaging, and others. There are different treatment options available for this disease such as drug medication, dialysis, surgery, hyperbaric oxygen therapy, and others. Calciphylaxis is diagnosed and treated by hospitals, clinics, ambulatory surgical centers, and others. Additionally, advancements in diagnosis methods are enhancing the early detection of this disease, thereby driving the market demand.
How is AI Transforming the Calciphylaxis Market?
The integration of AI is considerably transforming the calciphylaxis market. Moreover, AI-powered systems are used for enhancing diagnostic accuracy, facilitating personalized treatment strategies, and potentially accelerating the development of new therapies.
Moreover, AI solutions can analyze complex datasets, including imaging scans and patient data, to identify distinct patterns indicative of calciphylaxis, which leads to earlier and more accurate diagnoses. This further ensures timely interventions and development of tailored treatment plans. In addition, AI solutions can help develop personalized treatment strategies by analyzing individual patient data and tailoring treatment plans to their specific needs. Consequently, the above factors are anticipated to drive the market growth in the upcoming years.
Calciphylaxis Market Dynamics - (DRO) :
Key Drivers:
High Prevalence of End-Stage Renal Disease is Driving Calciphylaxis Market Growth
End-stage renal disease is a medical condition when the kidneys permanently fail to work. It causes vascular calcification and thrombotic occlusion of small blood vessels which lead to calciphylaxis. The cases of end-stage renal disease are rising due to an aging population, rising diabetes and hypertension burden, further driving the market.
- According to the United States Renal Data System 2023 Annual Data Report, more than 808,000 people are affected with end-stage renal disease in United States in 2023. These high cases of end-stage renal disease are leading to calciphylaxis due to calcium build-up in blood vessels.
Thus, the high prevalence of end-stage renal disease is leading to calciphylaxis market demand.
Technological Advancements in Diagnosis are Creating Calciphylaxis Market Demand
Technological advancements in diagnosis are enhancing early detection, reducing patient discomfort and improving diagnostic efficiency in calciphylaxis. It includes diagnostic methods such as fluorescence molecular imaging and high-resolution ultrasound. These methods provide detailed cross-sectional images of skin & skin lesions and assess calcification of tissues. Further, traditional skin biopsy leads to wounds and skin infections. To deal with this, companies are developing advanced skin biopsy technologies.
- In 2022, Trajan Scientific and Medical developed Harpera, a non-surgical skin biopsy technology. It is highly used in the diagnosis of calciphylaxis by taking sample skin lesions with painless intervention. Additionally, this technology is less invasive and has less risk of infection further improving the patient outcomes.
Hence, technological advancements in diagnosis are leading to calciphylaxis market expansion.
Key Restraints:
Lack of Standardized Treatment Guidelines is Constraining Calciphylaxis Market Growth
The lack of standardized treatment guidelines is significantly restraining the market due to the rarity and poor diagnosis of calciphylaxis. There is no unified diagnostic standard for calciphylaxis as well as there is a lack of effective early screening strategies. The absence of universally accepted protocols leads to delays in clinical decision making further affecting the treatment across hospitals and regions. Also, lack of extensive clinical trials and research collaboration is affecting patient treatment. Additionally, lack of standardized treatment guidelines affects patient outcomes, treatment accessibility, and drug development. Hence, lack of standardized treatment guidelines is constraining the market demand through absence of universally accepted protocols and insufficient treatment accessibility.
Future Opportunities :
Development of Novel Therapies are Expected to Create Calciphylaxis Market Opportunities
In calciphylaxis, there is low levels of proteins such as inorganic pyrophosphate and adenosine in the patients which leads to calcium build-up in blood vessels. The current treatments such as drug medication, dialysis, and hyperbaric oxygen therapy does not increase these protein levels leading to less survival rate. To address this, companies are developing novel protein therapies to improve patient outcomes and survival rates.
- In 2025, Inozyme Pharma announced positive results from phase 1 seaport 1 trial of INZ-701. INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase inorganic pyrophosphate and adenosine levels in the treatment of calciphylaxis. This will create market opportunities for the manufacturers due to rising demand for protein replacement in the treatment.
Hence, development of novel therapies are expected to create calciphylaxis market opportunities.
Calciphylaxis Market Segmental Analysis :
By Calciphylaxis Type:
Based on calciphylaxis type, the market is categorized into uremic and non-uremic.
Trends in Calciphylaxis Type:
- According to calciphylaxis market trends, the incidence of uremic type is high among end-stage renal disease patients.
- The prevalence of non-uremic type is growing due to rising cases of obesity, diabetes, and autoimmune diseases as per market trends.
The uremic segment accounted for the largest market share in the year 2024.
- Uremic calciphylaxis is a condition characterized by calcification and occlusion of small blood vessels in patients with end-stage renal disease.
- Treatment options for this condition includes phosphate binders, sodium thiosulfate and wound care.
- Further, this condition is most common in end-stage renal disease patients due to chronic imbalances in calcium & phosphate metabolism, and long-term dialysis.
- For instance, in 2024, research article published in American Journal of Homeopathic Medicine stated that annual incidence of uremic calciphylaxis is approximately 35 per 10,000 end-stage renal disease patients.
- Hence, uremic segment is dominating in the market due to high incidence and disrupted calcium-phosphate metabolism.
The non-uremic segment is expected to grow at the fastest CAGR over the forecast period.
- Non-uremic calciphylaxis is a condition characterized by calcification and occlusion of small blood vessels in patients without end-stage renal disease.
- The prevalence of this condition is rising due to growing cases of obesity, diabetes, and autoimmune diseases which leads to calcium build-up in blood vessels.
- The rising use of medications such as warfarin and corticosteroids which disrupt calcium metabolism also contribute to the growth of this condition.
- Additionally, metabolic disorders such as hyperparathyroidism and dyslipidemia also increase susceptibility of vascular calcification leading to non-uremic calciphylaxis.
- Thus, rising obesity cases and increased use of corticosteroids causes vascular calcification thereby leading to non-uremic calciphylaxis further driving the growth of the segment.
By Type:
Based on type, the market is categorized into diagnosis and treatment.
Trends in Type
- As per calciphylaxis market trends, advancements in skin biopsies are improving early and confirm diagnosis of the condition.
- Use of drug medications is growing in the treatment as per market trends.
The diagnosis segment accounted for the largest market share in the year 2024.
- Diagnosis is further categorized into skin biopsy, blood test, imaging, and others.
- In skin biopsy, a skin sample of a lesion or wound is taken and analyzed under microscope and using certain substances to cause color or chemical changes that confirm the diagnosis.
- While blood tests such as renal function tests and blood coagulation markers indicate the renal function and clotting time among the patients.
- Further, growing awareness is increasing visits to hospitals and dialysis centers thereby increasing diagnosis among the patients.
- Hence, diagnosis segment is dominating in the market due to growing awareness and diagnosis of calciphylaxis through skin biopsy and blood tests.
The treatment segment is expected to grow at the fastest CAGR over the forecast period.
- Treatment is further categorized into drug medication, dialysis, surgery, hyperbaric oxygen therapy, and others.
- Drug medications such as sodium thiosulfate and hexasodium phytate balances the calcium-sodium metabolism and prevents calcium build-up in the blood vessels.
- Further, to improve patient outcomes and survival rate hyperbaric oxygen therapy is increasingly used by healthcare professionals due to its several benefits.
- For instance, in 2024, research article published in Journal of the American Academy of Dermatology explained outcomes after hyperbaric oxygen therapy for the treatment of calciphylaxis. It encourages wounds healing and also improves skin lesions among the patients.
- Therefore, efficiency of hyperbaric oxygen therapy in treatment is lowering complications in the patients thereby driving the growth of the segment.
By End User:
Based on end-user, the market is categorized into hospitals, clinics, ambulatory surgical centers, and others.
Trends in End-User:
- As per market trends, investments in hospitals are growing, leading to enhanced diagnosis and treatment options for the patients.
- Preference for ambulatory surgical centers is growing due to cost effectiveness and accessibility as per market trends.
The hospitals segment accounted for the largest market share of 57.88% in the year 2024.
- Hospitals play a major role in calciphylaxis through advanced diagnosis methods and treatment options.
- They are widely preferred by the patients due to advanced technology, well-developed infrastructure and skilled healthcare professionals.
- Further, global population and cases of chronic diseases are growing. To cater this, countries are investing in the hospitals.
- For instance, according to Medical Buyer, investments in hospitals is increased by 24% in India in 2024 as compared to the year 2021. This growing investment is enhancing the access to diagnosis and treatment options for rare disease including calciphylaxis.
- Hence, the hospitals segment is dominating in the market due to growing investments and wide treatment options.
The ambulatory surgical centers segment is expected to grow at the fastest CAGR over the forecast period.
- An ambulatory surgical center is a healthcare facility that provides same day surgical care, including diagnostic and preventive procedures.
- The adoption of an ambulatory surgical center is growing due to its ability to handle a wide range of diagnostic methods such as skin biopsy, blood test, imaging, and minimally invasive surgeries for skin lesion grafting.
- The shift towards outpatient setting is growing driven by advancements in surgical techniques and imaging technology.
- This has contributed to the growing role of ambulatory surgical centers in the treatment of calciphylaxis patients.
- Thus, adoption of ambulatory surgical centers is rising in the management of calciphylaxis patients supported by advanced surgical techniques and improved clinical outcomes, thereby driving the growth of the segment.
Regional Analysis:
The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In 2024, North America accounted for the highest market share at 45.37% and was valued at USD 1,093.01 Million and is expected to reach USD 1,957.06 Million in 2032. In North America, United States accounted for the highest calciphylaxis market share of 73.04% during the base year of 2024. As per market analysis, North America holds a dominant position in the market due to government initiatives. The governments in the region are collaborating with research institutes for the development of effective treatment for calciphylaxis. Moreover, government agencies are also updating reimbursement policies for enhancing treatment for end-stage renal disease, further driving the market.
- In 2024, Centers for Medicare & Medicaid Services increased reimbursements to all end-stage renal facilities by 2.1% compared with 2023 in United States. These facilities are getting more funding per patient, which is improving access to advanced treatment for complications such as
Thus, North America is leading in the market due to government initiatives and access to advanced treatment as per analysis.
Asia-pacific is expected to witness the fastest CAGR of 10.9% over the forecast period of 2025-2032. According to calciphylaxis market analysis, the Asia Pacific region is growing rapidly driven by rising prevalence of end-stage renal disease. Countries such as China, India, Japan, and South Korea are major contributors in the market due to growing cases of dialysis patients. The increasing number of hospitals and dialysis centers is further driving the adoption of hyperbaric oxygen therapy and drug medications in the treatment of calciphylaxis. Hence, the calciphylaxis market share of Asia Pacific is experiencing rapid growth through rising prevalence of the end-stage renal disease and increasing number of hospitals & dialysis centers.
According to calciphylaxis market analysis, the Europe region is experiencing steady growth in the market driven by advanced diagnostic methods. The region is well developed with modern diagnostic technology and skilled nephrologists along with digital healthcare infrastructure. The governments in the region are also investing in research and development of rare diseases including calciphylaxis. It is further leading to calciphylaxis market expansion in the region.
The Middle East and Africa regions are experiencing gradual demand in the market, driven by increasing awareness about rare diseases and improving healthcare industry. Countries such as Dubai, UAE, and South Arica are major contributors in the market pharmaceutical companies and government organizations are collaborating to provide advanced treatments for calciphylaxis. Further, the ambulatory surgical centers in the region are offering surgical wound debridement for the treatment as per analysis.
As per analysis, the market in Latin America is driven by economic developments and partnerships with international health organizations. Countries such as Brazil, Mexico and Argentina are major contributors in the region due to advanced nephrology clinics. The rise of clinics has significantly impacted on the availability of diagnosis and treatment options for rare renal conditions. Additionally, patients in the region prefer hyperbaric oxygen therapy due to its effectivity in wound healing.
Top Key Players & Market Share Insights:
The calciphylaxis industry is highly competitive with major players providing services to the national and international markets. Key players are adopting several strategies in research and development (R&D) and product innovation to hold a strong position in the global calciphylaxis market. Key players in the calciphylaxis industry include-
- Sanifit (Spain)
- Amgen Inc. (United States)
- Biogen Inc (United States)
- AstraZeneca plc (United Kingdom)
- AbbVie Inc. (United States)
- CSL (Switzerland)
- Novartis International AG (Switzerland)
- Merck & Co., Inc. (United States)
- Eli Lilly and Company (United States)
- Roche Holding AG (Switzerland)
Recent Industry Developments :
Mergers and Acquisitions:
- In 2021, Vifor Pharma acquired Sanifit Therapeutics. It is an expanding nephrology portfolio of Vifor Pharma including SNF472 which is used for the treatment of calciphylaxis.
Calciphylaxis Market Report Insights:
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 4,662.91 Million |
| CAGR (2025-2032) | 8.6% |
| By Calciphylaxis Type |
|
| By Type |
|
| By End User |
|
| By Region |
|
| Key Players |
|
| North America | U.S. Canada Mexico |
| Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
| APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
| Middle East and Africa | GCC Turkey South Africa Rest of MEA |
| LATAM | Brazil Argentina Chile Rest of LATAM |
| Report Coverage |
|
Key Questions Answered in the Report
How big is the calciphylaxis market? +
In 2024, the calciphylaxis market is USD 2,409.59 million.
Which is the fastest-growing region in the calciphylaxis market? +
Asia Pacific is the fastest-growing region in the calciphylaxis market.
What specific segmentation details are covered in the calciphylaxis market? +
Calciphylaxis Type, Type and End-User are covered in the calciphylaxis market.
Who are the major players in the calciphylaxis market? +
Sanifit (Spain), Amgen Inc. (United States), and CSL (Switzerland) are some of the major players in the market.
